12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Company News  |  Deals

Intrexon, Ziopharm Oncology deal

Intrexon will purchase about 2.4 million shares of Ziopharm common stock, or 5% of Ziopharm's outstanding shares, for $11.6 million. The shares will be purchased at $4.80, a 2% premium to Ziopharms close of $4.72 on Jan. 6, before the deal was announced, in a private placement. Ziopharm also will issue...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >